Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD

International Journal of COPD

Volumn 2, Issue 3, 2007, Pages 191-204

  Miravitlles, Marc ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antibiotics; Chronic bronchitis; COPD; Exacerbations; Moxifloxacin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OXYGEN; PENICILLIN G; SHORT ACTING DRUG; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ERADICATION THERAPY; HAEMOPHILUS INFLUENZAE; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NAUSEA; OXYGEN THERAPY; PATIENT COMPLIANCE; RECURRENCE RISK; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BRONCHITIS, CHRONIC; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLINES; SPAIN; TREATMENT OUTCOME;

EID: 36148942465     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Adams SG, Melo J, Luther M, et al. 2000 A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest, 117:1345-52.
2. ALAT Work Group. 2004. Update to the Latin American Thoracic Society (ALAT) recommendations on infectious exacerbation of COPD. Arch Bronconeumol, 40:315-25.
3. Ball P, Stahlmann R, Kubin R, et al. 2004. Safety profile of oral and intravenous Moxifloxacin: Cumulative data from clinical trials and postmarketing studies. Clin Ther, 26:940-50.
4. Balter MS, La Forge J, Low DE, et al. 2003. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J, 10 (Suppl B): 3B-32B.
5. Blondeau J, 1999. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. JAntimocrob Chemother, 43: 1-11.
6. Cerveri I, Accordini S, Verlato G, et al. 2001. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J, 18:85-92.
7. Chodosh S, Deabate CA, Haverstock D, et al. 2000. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med, 94:18-27.
8. Chodosh S, Schreurs A, Siami G, et al. 1998. The efficacy of oral ciprofloxacin vs. clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis, 27:730-8.
9. Chodosh S. 2005. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest, 127:2231-6.
10. Davidson R, Cavalcanti R, Brunton JI, et al. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal penumonia. N Engl J Med, 346:747-50.
11. Dalhoff A, Shalit I. 2003. Immunomodulaotry effects of quinolones. Lancet Infect Dis, 3:359-71.
12. Deabate CA, Mathew CP, Warner JH, et al. 2000. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med, 94:1029-37.
13. De Benedetto F, Sevieri G. 2006. Chronic obstructive pulmonary disease (COPD) exacerbation and inflammation of the respiratory tract: clinical implication, prognostic consequences, and therapeutic strategies. Multidisciplinary Respiratory Medicine, 1:36-48.
14. De Marco R, Accordini S, Cerveri 1, et al. 2004. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax, 59:120-5.
15. Dewan NA, Rafique S, Kanwar B, et al. 2000. Acute exacerbation of COPD. Factors associated with poor outcome. Chest, 117:662-71.
16. Eller J, Ede A, Schaberg T, et al. 1998. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest, 113:1542-8.
17. Forrest A, Nix DE, Ballow CH, et al. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother, 37:1073-81.
18. Grassi C, Casali L, Curti E, et al. 2002. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother, 14:597-608.
19. Halls GA. 1993. The management of infections and antibiotic therapy: a European survey. J Antimicrob Chemother, 31:985-1000.
20. Hautamaki D, Bruya T, Kureishi A, et al. 2001. Short-course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. Today's Therapeutic Trends, 19:117-36.
21. Huchon GJ, Vergnenègre A, Neukirch F, et al. 2002. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J, 20:806-12.
22. Krasemann C, Meyer J, Tillotson G. 200 1. Evaluation of the clinical microbiology profile ofmoxifloxacin. Clin Infect Dis, 32(Suppl 1):S51-63.
23. Kreis SR, Herrera N, Golzar N, et al. 2000. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J Clin Outcomes Manag, 7:33-7.
24. Landen H, M611er M, Tillotson GS, et al. 2001. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res, 29:51-60.
25. Lister PD, Sanders CC, 2001. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother, 47:811-18.
26. Llor C, Naberan K, Cots JM, et al. 2004. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in Primary care centers. Int J Clin Pract, 58:937-44.
27. Loddenkemper R (Ed). 2003. The European Lung White Book. European Respiratory Society.
28. Lode H, Eller J, Linnhoff A, et al. 2004. Levofloxacin versus clarithromycin in COPD exacerbation: focus on infection-free interval. Eur Respir J, 24:947-53.
29. Lorenz J, Busch W, Thate-Waschke I-M, et al. 2001. Moxifloxacin in acute exacerbations of chronic bronchitis:clinical evaluation and assessment by patients. J Int Med Res, 29:61-73.
30. Macfarlane J, Holmes W, Gard P, et al. 2001. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax, 56:109-14.
31. Miravitlles M. 2000. Moxifloxacin: an antibiotic designed for use in the community. Eur Respir Rev, 10:161-9.
32. Miravitlles M. 2002a. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med, 9:191-197.
33. Miravitlles M. 2002b. Exacerbations ofchronic obstructive pulmonary disease: when are bacteria important?. Eur Respir J, 20 (Suppl 36):9s-19s.
34. Miravitlles M. 2005. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother, 6:283-293.
35. Miravitlles M, Anzueto A, Legnani D, et al. 2007b. Patient's perception of exacerbations of COPD - the PERCEIVE study. Respir Med, 101:453-60.
36. Miravitlles M, Espinosa C, Fernández-Laso E, et al. 1999. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest, 116:40-6.
37. Miravitlles M, Ferrer M, Pont A, et al. 2004a. for the IMPAC study group: Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax, 59:387-95.
38. Miravitlles M, Guerrero T, Mayordomo C, et al. 2000. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration, 67:495-501.
39. Miravitlles M, Llor C, Naberan K, et al. 2004b. The effect of various anti-microbial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Primary Care. Clin Drug Invest, 24:63-72.
40. Miravitlles M, Llor C, Naberan K, et al. 2005. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med, 99:955-65.
41. Miravitlles M, Martin Graczyk A. 2006. Tratamiento del paciente con EPOC agudizada. Guía de buena práctica clinica en Geriatría "Enfermedad Pulmonar Obstructiva Crónica". Normativa conjunta SEPAR-SEGG (Sociedad Española de Geriatría y Gerontología). Ed Elsevier Farma. 75-88.
42. Miravitlles M, Molina J, Brosa M. 2007a. Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis. Arch Bronconeumol, 43:16-21.
43. Miravitlles M, Murio C, Guerrero T. 2001a. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur Respir J, 17:928-33.
44. Miravitlles M, Murio C, Guerrero T, et al. 2002. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest, 121:1449-55.
45. Miravitlles M, Murio C, Guerrero T, et al. 2003a. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest, 123:784-91.
46. Miravitlles M, Ros F, Cobos A, et al. 2001b. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience. Int J Clin Pract, 55:437-44.
47. Miravitlles M, Torres A. 2004a. No more equivalence trials for antibiotics in exacerbations of COPD, please. Chest, 125:811-13.
48. MiravitlIes M, Torres A. 2004b. Antibiotics in exacerbations of COPD: lessons from the past. Eur Respir J, 24:896-7.
49. Miravitlles M, Zalacain R, Murio C, et al. 2003b. Speed of recovery from acute exacerbations of COPD after treatment with antimicrobials: Results of a two-year study. Clin Drug Invest, 23:439-50.
50. Monsó E, García-Aymerich J, Soler N, et al. 2003. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect, 131:799-804.
51. Murray CJL, Lopez AD. 1997.Altemative projections of mortality and disability by cause 1990-2020: Global Burden of Disease study. Lancet, 349:1498-504.
52. Nicolson P, Anderson P. 2000. The patient's burden: physical and psychological effects of acute exacerbations of chronic bronchitis. J Antimicrob Chemother, 45:25-32.
53. Niederman MS, Anzueto A, Sethi S, et al. 2006. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med, 100:1781-90.
54. Papi A, Bellettato CM, Braccioni F, et al. 2006. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med, 173:1114-21.
55. Perez-Gorricho B, Ripoll M. For the PACE Study Group. 2003. Does short-course antibiotic therapy better meet patient expectations? Int J Antimicrob Agents, 21:222-8.
56. Peto R, Lopez AD, Boreharn J, et al. 1992. Mortality from tobacco in developed countries: indirect estimation from vital statistics. Lancet, 339:1268-78.
57. Prescott E, Lange P, Vestbo J. 1995. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J, 8:1333-8.
58. Saravolatz L, Manzor O, Check C, et al. 2001. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother, 47:875-7.
59. Schaberg T, Ballin I, Huchon G, et al. 2001. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with amoxicillin-clavulanate oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res, 29:314-28.
60. Scheld WM. 2003. Maintaining fluoroquinolone efficacy:review of influencing factors. Emerg Infect Dis, 9:1-9.
61. Schentag J, Nix DE, Forrest A, et al. 1996. AUIC - the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother, 30:1024-8.
62. Seemungal TA, Donaldson GC, Paul EA, et al. 1998. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 157:1418-22.
63. Sethi S, Evans N, Grant BJ, et al. 2002. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med, 347:465-71.
64. Smith JA, Redman P, Woodhead MA. 1999. Antibiotic use in patients admitted with acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J, 13:835-8.
65. Sobradillo Pena V, Miravitlles M, Gabriel R, et al. 2000. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest, 119:991-9.
66. Soman A, Honeybourne D, Andrews J, et al. 1999. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother, 44:835-8.
67. Starakis I, Gogos CA, Bassaris H. 2004. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents, 23:129-37.
68. Stass H, Kubitza D. 1999. Pharmacokinetics and elimination of moxifloxacin afteroral and intravenous administration in man. J Antimicrob Chemother, 43 (Suppl B):83-90.
69. Stass H, Kubitza D, Schdhly U. 2001. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet, 40 (Suppl 1): 1-9.
70. Stratton CW 2003. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis, 9:10-16.
71. Sullivan JT, Woodruff M, Letiieri J, et al. 1999. Pharmacokinetics of a once-daily oral dose of moxifloxacin (BAY 12-8039), a new enantiomerically pure 8-methoxyquinolone. Antimicrob Agents Chemother, 43:2793-7.
72. Urueta-Robledo J, Ariza H, Jardim JR, et al. 2006. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American cohort. Respir Med, 100: 1564-11.
73. Wilson R, Kubin R, Ballin I, et al. 1999. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother, 44:501-13.
74. Wilson R, Allegra L, Huchon G, et al. 2004. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment n acute exacerbations of chronic bronchitis. Chest, 125:953-64.
75. Wilson R, Jones P, Schaberg T, et al. 2006. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax, 61:337-42.
76. Wise R. 1999. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone and its potential relation to therapeutic efficacy. Clin Drug Invest, 17:365-87.
77. Woodcock JM, Andrews JM, Boswell FJ, et al. 1997. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother, 41:101-6.